{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:35:41Z","timestamp":1786988141966,"version":"build-2736575974"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"am","delay-in-days":304,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017346","name":"Boehringer Ingelheim Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017346","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22fk0108637"],"award-info":[{"award-number":["JP22fk0108637"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22wm0125008"],"award-info":[{"award-number":["JP22wm0125008"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["21ek0410083h0002"],"award-info":[{"award-number":["21ek0410083h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008670","name":"Terumo Foundation for Life Sciences and Arts","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008670","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010740","name":"Asahi Kasei Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010740","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007325","name":"Kobayashi International Scholarship Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ejphar.2025.177537","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T09:50:02Z","timestamp":1742982602000},"page":"177537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Iguratimod, a promising therapeutic agent for COVID-19 that attenuates excessive inflammation in mouse models"],"prefix":"10.1016","volume":"996","author":[{"given":"Seiya","family":"Oba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5177-6413","authenticated-orcid":false,"given":"Tadashi","family":"Hosoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Kawata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoji","family":"Komiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Iwai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5647-8159","authenticated-orcid":false,"given":"Ryuji","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5151-3012","authenticated-orcid":false,"given":"Takayuki","family":"Kanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Ainai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.177537_bib1","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","author":"Abani","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2025.177537_bib2","doi-asserted-by":"crossref","first-page":"11386","DOI":"10.1021\/acsanm.1c01907","article-title":"Review of oxygenation with nanobubbles: possible treatment for hypoxic COVID-19 patients","volume":"4","author":"Afshari","year":"2021","journal-title":"ACS Appl. Nano Mater."},{"key":"10.1016\/j.ejphar.2025.177537_bib3","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/PL00000291","article-title":"An anti-rheumatic agent T-614 inhibits NF-\u03baB activation in LPS- and TNF-\u03b1-stimulated THP-1 cells without interfering with I\u03baB\u03b1 degradation","volume":"51","author":"Aikawa","year":"2002","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.ejphar.2025.177537_bib4","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1164\/rccm.201706-1172OC","article-title":"Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome","volume":"197","author":"Arabi","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejphar.2025.177537_bib5","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(22)02597-1","article-title":"Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial","volume":"401","author":"Butler","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2025.177537_bib6","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1080\/21645515.2020.1740560","article-title":"Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19","volume":"16","author":"Chen","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.ejphar.2025.177537_bib7","first-page":"252","article-title":"Associations of clinical characteristics and treatment regimens with the duration of viral RNA shedding in patients with COVID-19","volume":"98","author":"Chen","year":"2020","journal-title":"Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis."},{"key":"10.1016\/j.ejphar.2025.177537_bib8","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1213\/ANE.0000000000005292","article-title":"Aspirin use is associated with decreased mechanical ventilation, intensive care unit admission, and in-hospital mortality in hospitalized patients with coronavirus disease 2019","volume":"132","author":"Chow","year":"2021","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.ejphar.2025.177537_bib9","author":"Eslamdoust"},{"key":"10.1016\/j.ejphar.2025.177537_bib10","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early treatment for covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2025.177537_bib11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/cei\/uxad065","article-title":"Efficacy and safety of MAS825 (anti-IL-1\u03b2\/IL-18) in COVID-19 patients with pneumonia and impaired respiratory function","volume":"213","author":"Hakim","year":"2023","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ejphar.2025.177537_bib12","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.ejphar.2025.177537_bib13","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with covid-19","volume":"384","author":"Horby","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2025.177537_bib14","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2300155120","article-title":"Apple-shaped obesity: a risky soil for cytokine-accelerated severity in COVID-19","volume":"120","author":"Hosoya","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejphar.2025.177537_bib15","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2025.177537_bib16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1146\/annurev-micro-092611-150203","article-title":"A virological view of innate immune recognition","volume":"66","author":"Iwasaki","year":"2012","journal-title":"Annu. Rev. Microbiol."},{"key":"10.1016\/j.ejphar.2025.177537_bib17","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1126\/sciadv.abh3827","article-title":"A lethal mouse model for evaluating vaccine-associated enhanced respiratory disease during SARS-CoV-2 infection","volume":"8","author":"Iwata-Yoshikawa","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejphar.2025.177537_bib18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/mr\/roac017","article-title":"Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis\u2014secondary publication","volume":"33","author":"Kawahito","year":"2023","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.ejphar.2025.177537_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2024.156592","article-title":"Diverse pro-inflammatory ability of mutated spike protein derived from variant strains of SARS-CoV-2","volume":"178","author":"Kawata","year":"2024","journal-title":"Cytokine"},{"key":"10.1016\/j.ejphar.2025.177537_bib20","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.68563","article-title":"SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-\u03baB pathway","volume":"10","author":"Khan","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.ejphar.2025.177537_bib21","first-page":"2591","article-title":"Inhibitory effect of T-614 on tumor necrosis factor-alpha induced cytokine production and nuclear factor-kappaB activation in cultured human synovial cells","volume":"28","author":"Kohno","year":"2001","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.ejphar.2025.177537_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2024.167472","article-title":"Necroptosis in alveolar epithelial cells drives lung inflammation and injury caused by SARS-CoV-2 infection","volume":"1870","author":"Komiya","year":"2024","journal-title":"Biochim. Biophys. Acta, Mol. Basis Dis."},{"key":"10.1016\/j.ejphar.2025.177537_bib23","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.3389\/fimmu.2019.01521","article-title":"Divergent effects of a transient corticosteroid therapy on virus-specific quiescent and effector CD8(+) T cells","volume":"10","author":"Kumar","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2025.177537_bib24","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/s41591-021-01499-z","article-title":"Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial","volume":"27","author":"Kyriazopoulou","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2025.177537_bib25","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/sctm.20-0472","article-title":"Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: a double-blind, phase 1\/2a, randomized controlled trial","volume":"10","author":"Lanzoni","year":"2021","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.ejphar.2025.177537_bib26","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jcv.2004.07.006","article-title":"Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients","volume":"31","author":"Lee","year":"2004","journal-title":"J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol."},{"key":"10.1016\/j.ejphar.2025.177537_bib27","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S2213-2600(20)30404-5","article-title":"Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes","volume":"8","author":"Leisman","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ejphar.2025.177537_bib28","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1172\/JCI140617","article-title":"Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome","volume":"130","author":"Liu","year":"2020","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejphar.2025.177537_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1440584","article-title":"A systematic review and meta-analysis of the efficacy and safety of iguratimod in the treatment of inflammatory arthritis and degenerative arthritis","volume":"15","author":"Long","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177537_bib30","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.4049\/jimmunol.1300832","article-title":"A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide","volume":"191","author":"Luo","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2025.177537_bib31","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/cbdd.14136","article-title":"A review on computer-aided chemogenomics and drug repositioning for rational COVID-19 drug discovery","volume":"100","author":"Maghsoudi","year":"2022","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejphar.2025.177537_bib32","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/jmv.27405","article-title":"Role of toll-like receptors in modulation of cytokine storm signaling in SARS-CoV-2-induced COVID-19","volume":"94","author":"Manik","year":"2022","journal-title":"J. Med. Virol."},{"issue":"3","key":"10.1016\/j.ejphar.2025.177537_bib33","doi-asserted-by":"crossref","first-page":"L379","DOI":"10.1152\/ajplung.00010.2008","article-title":"Animal models of acute lung injury","volume":"295","author":"Matute-Bello","year":"2008","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.ejphar.2025.177537_bib34","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1080\/14397595.2018.1460230","article-title":"Safety and effectiveness of iguratimod in patients with rheumatoid arthritis: final report of a 52-week, multicenter postmarketing surveillance study","volume":"29","author":"Mimori","year":"2019","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.ejphar.2025.177537_bib35","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1126\/science.abb8925","article-title":"Cytokine release syndrome in severe COVID-19","volume":"368","author":"Moore","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2025.177537_bib36","article-title":"Effectiveness and safety of iguratimod treatment in patients with active rheumatoid arthritis in Chinese: a nationwide, prospective real-world study","volume":"10","author":"Mu","year":"2021","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.ejphar.2025.177537_bib37","first-page":"1520e7","article-title":"Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalized COVID-19 patients: results from a prospective observational study","volume":"27","author":"M\u00fchlemann","year":"2021","journal-title":"Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.ejphar.2025.177537_bib38","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s42003-021-02983-5","article-title":"SARS-CoV-2 infection induces a pro-inflammatory cytokine response through cGAS-STING and NF-\u03baB","volume":"5","author":"Neufeldt","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ejphar.2025.177537_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106922","article-title":"Antiviral effect and safety of nafamostat mesilate in patients with mild early-onset COVID-19: an exploratory multicentre randomized controlled clinical trial","volume":"62","author":"Okugawa","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejphar.2025.177537_bib40","doi-asserted-by":"crossref","first-page":"e4166","DOI":"10.1093\/cid\/ciaa1041","article-title":"Remdesivir for severe coronavirus disease 2019 (COVID-19) versus a cohort receiving standard of care","volume":"73","author":"Olender","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejphar.2025.177537_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.911810","article-title":"Effectiveness and safety of iguratimod monotherapy or combined with methotrexate in treating rheumatoid arthritis: a systematic review and meta-analysis","volume":"13","author":"Ouyang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177537_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-024-55696-0","article-title":"Severe COVID-19 and long COVID are associated with high expression of STING, cGAS and IFN-\u03b1","volume":"14","author":"Queiroz","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2025.177537_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.chemosphere.2022.135578","article-title":"CaZnO-based nanoghosts for the detection of ssDNA, pCRISPR and recombinant SARS-CoV-2 spike antigen and targeted delivery of doxorubicin","volume":"306","author":"Rabiee","year":"2022","journal-title":"Chemosphere"},{"key":"10.1016\/j.ejphar.2025.177537_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.curtheres.2021.100658","article-title":"The possible role of bruton tyrosine kinase inhibitors in the treatment of COVID-19: a review","volume":"96","author":"Rezaei","year":"2022","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"10.1016\/j.ejphar.2025.177537_bib45","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1080\/17476348.2020.1778470","article-title":"Multiple organ dysfunction in SARS-CoV-2: MODS-CoV-2","volume":"14","author":"Robba","year":"2020","journal-title":"Expet Rev. Respir. Med."},{"key":"10.1016\/j.ejphar.2025.177537_bib46","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in patients hospitalized with covid-19 pneumonia","volume":"384","author":"Salama","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2025.177537_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101489","article-title":"Baricitinib in hospitalised patients with COVID-19: a meta-analysis of randomised controlled trials","volume":"49","author":"Selvaraj","year":"2022","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.ejphar.2025.177537_bib48","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.2021.11330","article-title":"Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis","volume":"326","author":"Shankar-Hari","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2025.177537_bib49","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejphar.2025.177537_bib50","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb5883","article-title":"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice","volume":"12","author":"Sheahan","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejphar.2025.177537_bib51","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nrrheum.2016.112","article-title":"Affective disturbance in rheumatoid arthritis: psychological and disease-related pathways","volume":"12","author":"Sturgeon","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ejphar.2025.177537_bib52","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2492\/inflammregen.34.157","article-title":"The combined effects of iguratimod with anti-TNF^|^alpha; antibody on experimental arthritis models in mice","volume":"34","author":"Tanaka","year":"2014","journal-title":"Inflamm. Regen."},{"key":"10.1016\/j.ejphar.2025.177537_bib53","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","article-title":"The trinity of COVID-19: immunity, inflammation and intervention","volume":"20","author":"Tay","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejphar.2025.177537_bib54","doi-asserted-by":"crossref","first-page":"7176","DOI":"10.1038\/srep07176","article-title":"Glucocorticosteroids enhance replication of respiratory viruses: effect of adjuvant interferon","volume":"4","author":"Thomas","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2025.177537_bib55","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.ejphar.2025.177537_bib56","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a neutralizing antibody cocktail, in outpatients with covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2025.177537_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.791753","article-title":"SARS-CoV-2 N protein induces acute lung injury in mice via NF-\u0138B activation","volume":"12","author":"Xia","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.ejphar.2025.177537_bib58","first-page":"1160","article-title":"Evaluation of the associations between dry mouth, oral lesions, and orofacial pain with COVID-19: a systematic review and meta-analysis","volume":"13","author":"Yaghmoori","year":"2021","journal-title":"J. Pharm. Negat. Results"},{"key":"10.1016\/j.ejphar.2025.177537_bib59","first-page":"551","article-title":"Effect of a disease-modifying antirheumatic drug iguratimod (T-614) on inflammatory cytokine production","volume":"35","author":"Yamamoto","year":"2007","journal-title":"Jpn. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2025.177537_bib60","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41423-021-00793-7","article-title":"Dexamethasone ameliorates severe pneumonia but slightly enhances viral replication in the lungs of SARS-CoV-2-infected Syrian hamsters","volume":"19","author":"Yuan","year":"2022","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.ejphar.2025.177537_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1189142","article-title":"Efficacy and safety of iguratimod in the treatment of rheumatic and autoimmune diseases: a meta-analysis and systematic review of 84 randomized controlled trials","volume":"14","author":"Zeng","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177537_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13073-023-01227-x","article-title":"SARS-CoV-2 infection induces a long-lived pro-inflammatory transcriptional profile","volume":"15","author":"Zhang","year":"2023","journal-title":"Genome Med."},{"key":"10.1016\/j.ejphar.2025.177537_bib63","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41440-023-01460-2","article-title":"The role of SARS-CoV-2-mediated NF-\u03baB activation in COVID-19 patients","volume":"47","author":"Zhou","year":"2024","journal-title":"Hypertens. Res."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925002912?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925002912?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:31:22Z","timestamp":1762144282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925002912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":63,"alternative-id":["S0014299925002912"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177537","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Iguratimod, a promising therapeutic agent for COVID-19 that attenuates excessive inflammation in mouse models","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177537","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"177537"}}